PF4 and blood coagulation disease: Because PF4 is a major target of autoantibodies in COVID-19 vaccine-associated coagulopathies, lack of clear cross-reactivity of SARS-CoV-2 antibodies to PF4 again helps to explain the safety of the spike-protein-based vaccines.